Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 101–200 of 1,008
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A., Schulte, C., Maetzler, W., Gasser, T., & Berg, D. (2015) · Movement Disorders · doi:10.1002/mds.26071 · Cited by 267
Self-citationGenetic Analysis of Pathways to Parkinson Disease
Hardy, J. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.014 · Cited by 274
GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
Riboldi, G. M., & Di Fonzo, A. B. (2019) · Cells · doi:10.3390/cells8040364 · Cited by 274
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
Cognitive impairment and dementia in Parkinson's disease
Pagonabarraga, J., & Kulisevsky, J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.029 · Cited by 257
GBA-associated PD presents with nonmotor characteristics
Brockmann, K., Srulijes, K., Hauser, A.-K., Schulte, C., Csoti, I., Gasser, T., & Berg, D. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab77 · Cited by 268
Self-citationMutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis
Bras, J., Verloes, A., Schneider, S. A., Mole, S. E., & Guerreiro, R. J. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds089 · Cited by 266
Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal–lysosomal pathway
Tofaris, G. K., Kim, H. T., Hourez, R., Jung, J.-W., Kim, K. P., & Goldberg, A. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109356108 · Cited by 271
The Genetics of Parkinson’s Disease and Implications for Clinical Practice
Day, J. O., & Mullin, S. (2021) · Genes · doi:10.3390/genes12071006 · Cited by 234
Cognitive performance of GBA mutation carriers with early-onset PD: The CORE-PD study
Alcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M.-X., Rosado, L., Orbe Reilly, M., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318253d54b · Cited by 262
Self-citationSpecifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
Liu, G., Boot, B., Locascio, J. J., Jansen, I. E., Winder‐Rhodes, S., Eberly, S., Elbaz, A., Brice, A., Ravina, B., van Hilten, J. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24781 · Cited by 263
Self-citationLewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia
Gomperts, S. N. (2016) · Continuum · doi:10.1212/con.0000000000000309 · Cited by 235
Mitochondrial and lysosomal biogenesis are activated following PINK 1/parkin‐mediated mitophagy
Ivankovic, D., Chau, K., Schapira, A. H. V., & Gegg, M. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13412 · Cited by 264
Genetic risk factors in Parkinson’s disease
Billingsley, K. J., Bandres-Ciga, S., Saez-Atienzar, S., & Singleton, A. B. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2817-y · Cited by 249
“…on, a multicenter study conducted by Sidransky et al. showed that heterozygousGBAmutations are the largest genetic risk factor for developing PD, enhancing one’s risk approximately 5-fold and highlighting the importance of the lysosomal pathway in the pathogenesis of PD (Sidransky et al. 2009).”
BackgroundSelf-citationGenetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease
Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015) · Autophagy · doi:10.1080/15548627.2015.1067364 · Cited by 260
Self-citationProtein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders
van den Berg, M. M. J., Krauskopf, J., Ramaekers, J. G., Kleinjans, J. C. S., Prickaerts, J., & Briedé, J. J. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101732 · Cited by 253
Emptying the stores: lysosomal diseases and therapeutic strategies
Platt, F. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.214 · Cited by 244
“Most notably, being a carrier for a Gaucher disease causing mutation confers the highest genetic risk factor for developing Parkinson's disease [45-49].”
BackgroundConvergence of miRNA Expression Profiling, α-Synuclein Interacton and GWAS in Parkinson's Disease
Martins, M., Rosa, A., Guedes, L. C., Fonseca, B. V., Gotovac, K., Violante, S., Mestre, T., Coelho, M., Rosa, M. M., Martin, E. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025443 · Cited by 245
Sardi, S. P., Clarke, J., Viel, C., Chan, M., Tamsett, T. J., Treleaven, C. M., Bu, J., Sweet, L., Passini, M. A., Dodge, J. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220464110 · Cited by 251
Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations
Li, H., Ham, A., Ma, T. C., Kuo, S.-H., Kanter, E., Kim, D., Ko, H. S., Quan, Y., Sardi, S. P., Li, A., et al. (2019) · Autophagy · doi:10.1080/15548627.2018.1509818 · Cited by 243
“Homozygous GBA mutations cause Gaucher disease (GD), the most common lysosomal disorder, whereas heterozygous GBA mutations are the most common genetic risk factor for Parkinson disease (PD), present in 7–20% of all PD cases [1].”
BackgroundLysosomal dysfunction in neurodegeneration: emerging concepts and methods
Udayar, V., Chen, Y., Sidransky, E., & Jagasia, R. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2021.12.004 · Cited by 240
Self-citationTherapeutic approaches to target alpha-synuclein pathology
Brundin, P., Dave, K. D., & Kordower, J. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.003 · Cited by 242
“Mutations in the GBA1 gene, which encodes for GCase, have been identified as causative for Gaucher disease, a rare lysosomal storage disorder and represent the most common genetic risk factor for PD (Sidransky et al., 2009).”
Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease
Taguchi, Y. V., Liu, J., Ruan, J., Pacheco, J., Zhang, X., Abbasi, J., Keutzer, J., Mistry, P. K., & Chandra, S. S. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1525-17.2017 · Cited by 243
Parkinson's Disease Genetics and Pathophysiology
Vázquez-Vélez, G. E., & Zoghbi, H. Y. (2021) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-100720-034518 · Cited by 232
Mielke, M. M., Maetzler, W., Haughey, N. J., Bandaru, V. V. R., Savica, R., Deuschle, C., Gasser, T., Hauser, A.-K., Gräber-Sultan, S., Schleicher, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073094 · Cited by 232
Self-citationIannielli, A., Bido, S., Folladori, L., Segnali, A., Cancellieri, C., Maresca, A., Massimino, L., Rubio, A., Morabito, G., Caporali, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.089 · Cited by 239
The relationship between glucocerebrosidase mutations and Parkinson disease
Migdalska‐Richards, A., & Schapira, A. H. V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13385 · Cited by 231
The Role of Sex and Sex Hormones in Neurodegenerative Diseases
Vegeto, E., Villa, A., Della Torre, S., Crippa, V., Rusmini, P., Cristofani, R., Galbiati, M., Maggi, A., & Poletti, A. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz005 · Cited by 232
Blauwendraat, C., Reed, X., Krohn, L., Heilbron, K., Bandres-Ciga, S., Tan, M., Gibbs, J. R., Hernandez, D. G., Kumaran, R., Langston, R., et al. (2020) · Brain · doi:10.1093/brain/awz350 · Cited by 236
Self-citationPenetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
Anheim, M., Elbaz, A., Lesage, S., Durr, A., Condroyer, C., Viallet, F., Pollak, P., Bonaïti, B., Bonaïti-Pellié, C., & Brice, A. (2012) · Neurology · doi:10.1212/wnl.0b013e318245f476 · Cited by 238
Self-citationMagalhaes, J., Gegg, M. E., Migdalska-Richards, A., Doherty, M. K., Whitfield, P. D., & Schapira, A. H. V. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw185 · Cited by 234
The benefits and mechanisms of exercise training for Parkinson's disease
Feng, Y.-S., Yang, S.-D., Tan, Z.-X., Wang, M.-M., Xing, Y., Dong, F., & Zhang, F. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117345 · Cited by 218
Aflaki, E., Borger, D. K., Moaven, N., Stubblefield, B. K., Rogers, S. A., Patnaik, S., Schoenen, F. J., Westbroek, W., Zheng, W., Sullivan, P., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0636-16.2016 · Cited by 227
Self-citationShared dysregulated pathways lead to Parkinson's disease and diabetes
Santiago, J. A., & Potashkin, J. A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.01.002 · Cited by 227
Bourdenx, M., Daniel, J., Genin, E., Soria, F. N., Blanchard-Desce, M., Bezard, E., & Dehay, B. (2016) · Autophagy · doi:10.1080/15548627.2015.1136769 · Cited by 215
The genetic landscape of Parkinson's disease
Lunati, A., Lesage, S., & Brice, A. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.08.004 · Cited by 215
Self-citationBras, J., Guerreiro, R., Darwent, L., Parkkinen, L., Ansorge, O., Escott-Price, V., Hernandez, D. G., Nalls, M. A., Clark, L. N., Honig, L. S., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu334 · Cited by 230
Self-citationReversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide
Zunke, F., Moise, A. C., Belur, N. R., Gelyana, E., Stojkovska, I., Dzaferbegovic, H., Toker, N. J., Jeon, S., Fredriksen, K., & Mazzulli, J. R. (2018) · Neuron · doi:10.1016/j.neuron.2017.12.012 · Cited by 223
Glucocerebrosidase and Parkinson disease: Recent advances
Schapira, A. H. V. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.03.013 · Cited by 219
Progress in unraveling the genetic etiology of Parkinson disease in a genomic era
Verstraeten, A., Theuns, J., & Van Broeckhoven, C. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.01.004 · Cited by 226
Woodard, C. M., Campos, B. A., Kuo, S.-H., Nirenberg, M. J., Nestor, M. W., Zimmer, M., Mosharov, E. V., Sulzer, D., Zhou, H., Paull, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.023 · Cited by 222
Self-citationMitophagy in Parkinson’s Disease: From Pathogenesis to Treatment
Liu, J., Liu, W., Li, R., & Yang, H. (2019) · Cells · doi:10.3390/cells8070712 · Cited by 222
“GBA1 encodes the lysosomal enzyme glucosylceramidase beta/β-glucocerebrosidase, and its heterozygous mutations are among the most common genetic risk factors of PD [116].”
BackgroundInflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
The risk of Parkinson's disease in type 1 Gaucher disease
Bultron, G., Kacena, K., Pearson, D., Boxer, M., Yang, R., Sathe, S., Pastores, G., & Mistry, P. K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9055-0 · Cited by 223
Comparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease and GBA Heterozygotes
Alcalay, R. N., Dinur, T., Quinn, T., Sakanaka, K., Levy, O., Waters, C., Fahn, S., Dorovski, T., Chung, W. K., Pauciulo, M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.313 · Cited by 217
Self-citationDavis, M. Y., Johnson, C. O., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Chen-Plotkin, A., Van Deerlin, V. M., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2245 · Cited by 215
Self-citationN-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases
Holmay, M. J., Terpstra, M., Coles, L. D., Mishra, U., Ahlskog, M., Öz, G., Cloyd, J. C., & Tuite, P. J. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31829ae713 · Cited by 216
Progressive decline of glucocerebrosidase in aging and Parkinson's disease
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hallett, P., & Isacson, O. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.177 · Cited by 210
Genetics of Parkinson's disease – state of the art, 2013
Bonifati, V. (2014) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70009-9 · Cited by 210
Ambroxol effects in glucocerebrosidase and α‐synuclein transgenic mice
Migdalska‐Richards, A., Daly, L., Bezard, E., & Schapira, A. H. V. (2016) · Annals of Neurology · doi:10.1002/ana.24790 · Cited by 204
de Araujo, M. E. G., Liebscher, G., Hess, M. W., & Huber, L. A. (2020) · Traffic · doi:10.1111/tra.12714 · Cited by 203
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease
Mata, I. F., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Chen‐Plotkin, A., Van Deerlin, V. M., Ritz, B., Rausch, R., Factor, S. A., Wood‐Siverio, C., et al. (2016) · Movement Disorders · doi:10.1002/mds.26359 · Cited by 204
Self-citationMolecular and clinical prodrome of Parkinson disease: implications for treatment
Schapira, A. H. V., & Tolosa, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.52 · Cited by 202
Cerebrospinal fluid biomarkers in Parkinson disease
Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209
Evolution of Prodromal Clinical Markers of Parkinson Disease in a GBA Mutation–Positive Cohort
Beavan, M., McNeill, A., Proukakis, C., Hughes, D. A., Mehta, A., & Schapira, A. H. V. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2950 · Cited by 205
Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis
van Es, M. A., Schelhaas, H. J., van Vught, P. W. J., Ticozzi, N., Andersen, P. M., Groen, E. J. N., Schulte, C., Blauw, H. M., Koppers, M., Diekstra, F. P., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22611 · Cited by 200
Self-citationMolecular genetics of Parkinson’s disease: Contributions and global trends
Funayama, M., Nishioka, K., Li, Y., & Hattori, N. (2023) · Journal of Human Genetics · doi:10.1038/s10038-022-01058-5 · Cited by 189
Nalls, M. A., McLean, C. Y., Rick, J., Eberly, S., Hutten, S. J., Gwinn, K., Sutherland, M., Martinez, M., Heutink, P., Williams, N. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00178-7 · Cited by 204
Self-citationFerroptosis in Parkinson's disease: Molecular mechanisms and therapeutic potential
Ding, X.-S., Gao, L., Han, Z., Eleuteri, S., Shi, W., Shen, Y., Song, Z.-Y., Su, M., Yang, Q., Qu, Y., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102077 · Cited by 193
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616152114 · Cited by 203
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
Zeng, X.-S., Geng, W.-S., Jia, J.-J., Chen, L., & Zhang, P.-P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00109 · Cited by 193
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage
Cleeter, M. W. J., Chau, K.-Y., Gluck, C., Mehta, A., Hughes, D. A., Duchen, M., Wood, N. W., Hardy, J., Mark Cooper, J., & Schapira, A. H. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.10.010 · Cited by 201
Kim, S., Wong, Y. C., Gao, F., & Krainc, D. (2021) · Nature Communications · doi:10.1038/s41467-021-22113-3 · Cited by 199
Regulation of sphingomyelin metabolism
Bienias, K., Fiedorowicz, A., Sadowska, A., Prokopiuk, S., & Car, H. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.12.008 · Cited by 198
“lysosomal enzyme, glucocerebrosidase, which is an important risk factor for PD development [171] as well as in patients with sporadic PD no alterations in SM content were observed [172].”
BackgroundImpaired intracellular trafficking defines early Parkinson's disease
Hunn, B. H. M., Cragg, S. J., Bolam, J. P., Spillantini, M.-G., & Wade-Martins, R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.009 · Cited by 184
Ballabio, A. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505966 · Cited by 190
Gene-based therapies for neurodegenerative diseases
Sun, J., & Roy, S. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00778-1 · Cited by 187
The role of Ca2+ signaling in Parkinson's disease
Zaichick, S. V., McGrath, K. M., & Caraveo, G. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.028738 · Cited by 188
“Individuals carrying a subset of these GBA mutations are 20 times more susceptible to developing PD (Beavan and Schapira, 2013; Dehay et al., 2013; Sidransky et al., 2009).”
BackgroundUsing genome-wide complex trait analysis to quantify ‘missing heritability’ in Parkinson’s disease
Keller, M. F., Saad, M., Bras, J., Bettella, F., Nicolaou, N., Simon-Sanchez, J., Mittag, F., Buchel, F., Sharma, M., Gibbs, J. R., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds335 · Cited by 190
Self-citationEpidemiology, environmental risk factors and genetics of Parkinson's disease
Delamarre, A., & Meissner, W. G. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.01.001 · Cited by 175
The prediagnostic phase of Parkinson's disease
Noyce, A. J., Lees, A. J., & Schrag, A.-E. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311890 · Cited by 173
Recent Advances in Biomarkers for Parkinson’s Disease
He, R., Yan, X., Guo, J., Xu, Q., Tang, B., & Sun, Q. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00305 · Cited by 175
Neuron-Astrocyte Interactions in Parkinson’s Disease
Miyazaki, I., & Asanuma, M. (2020) · Cells · doi:10.3390/cells9122623 · Cited by 186
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I., & Sidransky, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0741-7 · Cited by 181
Self-citationLRRK2 at the interface of autophagosomes, endosomes and lysosomes
Roosen, D. A., & Cookson, M. R. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0140-1 · Cited by 185
“GBA Risk factor Lysosomal protease [14, 100]”
Autophagic and endo-lysosomal dysfunction in neurodegenerative disease
Malik, B. R., Maddison, D. C., Smith, G. A., & Peters, O. M. (2019) · Molecular Brain · doi:10.1186/s13041-019-0504-x · Cited by 184
“Genetic studies of PD patients have identified a strong association with heterozygosity for GBA loss-of-function mutations and increased risk of developing PD [252].”
BackgroundCerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients
Parnetti, L., Paciotti, S., Eusebi, P., Dardis, A., Zampieri, S., Chiasserini, D., Tasegian, A., Tambasco, N., Bembi, B., Calabresi, P., et al. (2017) · Movement Disorders · doi:10.1002/mds.27136 · Cited by 178
The genetic architecture of mitochondrial dysfunction in Parkinson’s disease
Larsen, S. B., Hanss, Z., & Krüger, R. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2768-8 · Cited by 181
Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein
Bae, E.-J., Yang, N.-Y., Song, M., Lee, C. S., Lee, J. S., Jung, B. C., Lee, H.-J., Kim, S., Masliah, E., Sardi, S. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms5755 · Cited by 177
Meireles, J., & Massano, J. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00088 · Cited by 172
“Some years ago, heterozygous GBA mutations have been associated with a higher risk of PD (Aharon-Peretz et al., 2004; Sidransky et al., 2009), and data even suggested that these patients could have an increased risk for cognitive impairment.”
BackgroundGenetics and Epigenetics of Parkinson's Disease
Coppedè, F. (2012) · The Scientific World Journal · doi:10.1100/2012/489830 · Cited by 175
Genetics and genomics of Parkinson’s disease
Lin, M. K., & Farrer, M. J. (2014) · Genome Medicine · doi:10.1186/gm566 · Cited by 179
Self-citationTargeted Therapies for Parkinson's Disease: From Genetics to the Clinic
Sardi, S. P., Cedarbaum, J. M., & Brundin, P. (2018) · Movement Disorders · doi:10.1002/mds.27414 · Cited by 170
Autophagy and Neuronal Cell Death in Neurological Disorders
Nixon, R. A., & Yang, D.-S. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008839 · Cited by 181
Lysosomal Dysfunction and α‐Synuclein Aggregation in Parkinson's Disease: Diagnostic Links
Moors, T., Paciotti, S., Chiasserini, D., Calabresi, P., Parnetti, L., Beccari, T., & van de Berg, W. D. J. (2016) · Movement Disorders · doi:10.1002/mds.26562 · Cited by 173
GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers
Kim, S., Yun, S. P., Lee, S., Umanah, G. E., Bandaru, V. V. R., Yin, X., Rhee, P., Karuppagounder, S. S., Kwon, S.-H., Lee, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700465115 · Cited by 178
Yap, T. L., Gruschus, J. M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., & Lee, J. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237859 · Cited by 174
Self-citationThe p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease
Gan-Or, Z., Ozelius, L. J., Bar-Shira, A., Saunders-Pullman, R., Mirelman, A., Kornreich, R., Gana-Weisz, M., Raymond, D., Rozenkrantz, L., Deik, A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31828f180e · Cited by 175
Self-citationIs Parkinson’s disease a lysosomal disorder?
Klein, A. D., & Mazzulli, J. R. (2018) · Brain · doi:10.1093/brain/awy147 · Cited by 172
“However, a multi-centre analysis of idiopathic Parkinson’s disease patients demonstrated that loss-of-function mutations in one allele of GBA1 is a significant risk factor for developing disease (Sidransky et al., 2009).”
BackgroundRecent developments in the treatment of Parkinson's Disease
Stoker, T. B., & Barker, R. A. (2020) · F1000Research · doi:10.12688/f1000research.25634.1 · Cited by 166
Goldstein, D. S., Kopin, I. J., & Sharabi, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.006 · Cited by 165
Brain Disorders Due to Lysosomal Dysfunction
Fraldi, A., Klein, A. D., Medina, D. L., & Settembre, C. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014031 · Cited by 170
“Several familial forms of PD present heterozygous mutations in the gene encoding for the lysosomal enzyme βglucocerebrosidase (GBA), and homozygous mutations cause Gaucher’s disease, a neurovisceral degenerative LSD (Sidransky et al. 2009).”
BackgroundGaucher disease: Progress and ongoing challenges
Mistry, P. K., Lopez, G., Schiffmann, R., Barton, N. W., Weinreb, N. J., & Sidransky, E. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.11.006 · Cited by 165
Self-citationLiu, X., Cheng, R., Verbitsky, M., Kisselev, S., Browne, A., Mejia-Sanatana, H., Louis, E. D., Cote, L. J., Andrews, H., Waters, C., et al. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-104 · Cited by 168
Self-citationJ. Irwin, D., & I. Hurtig, H. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000444 · Cited by 163
Huebecker, M., Moloney, E. B., van der Spoel, A. C., Priestman, D. A., Isacson, O., Hallett, P. J., & Platt, F. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0339-z · Cited by 165
The role of inflammation in sporadic and familial Parkinson’s disease
Deleidi, M., & Gasser, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1352-y · Cited by 167
Self-citationGenetic basis of Parkinson's disease: inheritance, penetrance, and expression
Gasser, T. (2011) · The Application of Clinical Genetics · doi:10.2147/tacg.s11639 · Cited by 157
Self-citation
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.